Enzo Biochem (NYSE:ENZ) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Enzo Biochem (NYSE:ENZ) in a research note issued on Monday. The firm set a “hold” rating on the medical research company’s stock.

Enzo Biochem Stock Performance

Shares of Enzo Biochem stock opened at $1.13 on Monday. Enzo Biochem has a one year low of $0.99 and a one year high of $1.50. The firm has a fifty day moving average of $1.12 and a two-hundred day moving average of $1.12.

Hedge Funds Weigh In On Enzo Biochem

A hedge fund recently raised its stake in Enzo Biochem stock. XTX Topco Ltd lifted its stake in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 94.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 28,262 shares of the medical research company’s stock after purchasing an additional 13,735 shares during the quarter. XTX Topco Ltd owned about 0.05% of Enzo Biochem worth $31,000 at the end of the most recent quarter. 36.90% of the stock is currently owned by institutional investors.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.